Safety and efficacy of long-term mild hypothermia for severe traumatic brain injury with refractory intracranial hypertension (LTH-1): A multicenter randomized controlled trial
Jiyuan Hui,Junfeng Feng,Yue Tu,Weituo Zhang,Chunlong Zhong,Min Liu,Yuhai Wang,Liansheng Long,Ligang Chen,Jinfang Liu,Chaohui Mou,Binghui Qiu,Xianjian Huang,Qibing Huang,Nu Zhang,Xiaofeng Yang,Chaohua Yang,Lihong Li,Rong Ma,Xiang Wu,Jin Lei,Yong Jiang,Liang Liu,Guoyi Gao,Jiyao Jiang
DOI: https://doi.org/10.1016/j.eclinm.2021.100732
IF: 15.1
2021-02-01
EClinicalMedicine
Abstract:BackgroundTherapeutic hypothermia may need prolonged duration for the patients with severe traumatic brain injury (sTBI).MethodsThe Long-Term Hypothermia trial was a prospective, multicenter, randomized, controlled clinical trial to examine the safety and efficacy in adults with sTBI. Eligible patients were 18–65, Glasgow Coma Scale score at 4 to 8, and initial intracranial pressure (ICP) ≥ 25 mm Hg, randomly assigned to the long-term mild hypothermia group (34–35 °C for 5 days) or normothermia group at 37 °C. The primary outcome was the Glasgow outcome scale (GOS) at 6 months. Secondary outcomes included ICP control, complications and laboratory findings, the length of ICU and hospital stay, and GOS at 6 months in patients with initial ICP ≥ 30 mm Hg. This trial is registered with ClinicalTrials.gov, NCT01886222.Findings302 patients were enrolled from June 25, 2013, to December 31, 2018, with 6 months follow-up in 14 hospitals, 156 in hypothermia group and 146 in normothermia group. There was no difference in favorable outcome (OR 1·55, 95%CI 0·91–2·64; P = 0·105) and in mortality (P = 0·111) between groups. In patients with an initial ICP ≥ 30 mm Hg, hypothermic treatment significantly increased favorable outcome over normothermia group (60·82%, 42·71%, respectively; OR 1·861, 95%CI 1·031–3·361; P = 0·039). Long-term mild hypothermia did not increase the incidences of complications.InterpretationLong-term mild hypothermia did not improve the neurological outcomes. However, it may be a potential option in sTBI patients with initial ICP ≥ 30 mm Hg.Funding: Shanghai municipal government and Shanghai Jiao Tong University/School of Medicine.